Steven Park, MD
Medical Oncology · Concord, NCNPI 1891707709
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Seagen Inc. accounts for 60.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $8,852 and has fallen 53.5% since, to $4,119 in 2025.
Across 21 payments — averaging $692.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$9K
- Ipsen Bioscience Inc.$4K
- ADC Therapeutics America, Inc.$1K
- Epizyme, Inc.$165
- Gilead$60
- Adaptive Biotechnologies Corporation$19
Across 163 payments — averaging $22,129 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$2.9M
- Epizyme, Inc.$621K
- Takeda Pharmaceuticals U.S.A., Inc.$47K
- Astrazeneca UK Limited$28K
- Novartis$4K
- Verastem, Inc.$3K
- plus $108 from 1 others
What the payments were for
- Consulting fees$5,50038%
- Speaking & faculty fees$6,50045%
- Travel & lodging$2,13015%
- Food & beverage$4053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 16 | $8,792 |
| Ipsen Bioscience Inc. | 1 | $4,100 |
| ADC Therapeutics America, Inc. | 1 | $1,400 |
| Epizyme, Inc. | 1 | $165 |
| Gilead | 1 | $60 |
| Adaptive Biotechnologies Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,536 in reported general payments places this provider in the 75th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 21 | $310,003 |
| BrukinsaZanubrutinib | 21 | $305,728 |
| RevlimidLenalidomide | 11 | $204,360 |
| Acyclovir | 24 | $319 |
| Prednisone | 11 | $29 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Concord
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Thomas StinchcombeChapel Hill$281K
- Steven SorscherWinston Salem$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.